Overexpression of both TFPIα and TFPIβ induces apoptosis and expression of genes involved in the death receptor pathway in breast cancer cells

Molecular Carcinogenesis

Volumn 49, Issue 11, 2010, Pages 951-963

  Stavik, Benedicte ^a,b   Skretting, Grethe ^a   Sletten, Marit ^a   Sandset, Per Morten ^a,b   Iversen, Nina ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Knockdown; Proliferation; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

CASPASE 3; MESSENGER RNA; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR ALPHA; TISSUE FACTOR PATHWAY INHIBITOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; DEATH RECEPTOR; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; SMALL INTERFERING RNA; TUMOR MARKER;

APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; DNA FRAGMENTATION; ENZYME ACTIVITY; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; ADENOCARCINOMA; BREAST TUMOR; DRUG ANTAGONISM; FEMALE; GENETICS; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENOCARCINOMA; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LIPOPROTEINS; RECEPTORS, DEATH DOMAIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 78149252353     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20679     Document Type: Article

References (30)

1. Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer and thrombosis: From molecular mechanisms to clinical presentations. J Thromb Haemost 2007; 5: 246-254.
2. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001; 102: V215-V224.
3. Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol 2002; 3: 27-34.
4. Cliffton EE, Agostino D. Irradiation and anticoagulant therapy to prevent pulmonary metastases of the V2 carcinoma in rabbits. Radiology 1963; 80: 236-243.
5. Agostino D, Cliffton EE, Girolami A. Effect of prolonged coumadin treatment on production of pulmonary metastases in rat. Cancer 1966; 19: 284-288.
6. Lee AE, Rogers LA, Longcroft JM, Jeffery RE. Reduction of metastasis in a murine mammary tumour model by heparin and polyinosinic-polycytidylic acid. Clin Exp Metastasis 1990; 8: 165-171.
7. Falanga A, Piccioli A. Effect of anticoagulant drugs in cancer. Curr Opin Pulm Med 2005; 11: 403-407.
8. Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in postheparin plasma and in plasma from cancer-patients. Blood Coagul Fibrinolysis 1991; 2: 713-721.
9. Iversen N, Lindahl AK, Abildgaard U. Elevated plasma levels of the factor Xa-TFPI complex in cancer patients. Thromb Res 2002; 105: 33-36.
10. Negaard HFS, Eilertsen AL, Dahm A, Iversen PO, Ostenstad B, Sandset PM. Decreased lung cancer survival with hormone-replacement therapy: Caused by a decreased tissue factor pathway inhibitor level? J Clin Oncol 2006; 24: 2683-2684.
11. Sierko E, Wojtukiewicz MZ, Zimnoch L, Kisiel W. Expression of tissue factor pathway inhibitor (TFPI) in human breast and colon cancer tissue. Thromb Haemost 2010; 103: 198-204.
12. Kurer MA. Protein and mRNA expression of tissue factor pathway inhibitor-1 (TFPI-1) in breast, pancreatic and colorectal cancer cells. Mol Biol Rep 2007; 34: 221-224.
13. Price GC, Thompson SA, Kam PCA. Tissue factor and tissue factor pathway inhibitor. Anaesthesia 2004; 59: 483-492.
14. Hamuro T, Kamikubo Y, Nakahara Y, Miyamoto S, Funatsu A. Human recombinant tissue factor pathway inhibitor induces apoptosis in cultured human endothelial cells. FEBS Lett 1998; 421: 197-202.
15. Lin YF, Zhang N, Guo HS, et al. Recombinant tissue factor pathway inhibitor induces apoptosis in cultured rat mesangial cells via its Kunitz-3 domain and C-terminal through inhibiting PI3-kinase/Akt pathway. Apoptosis 2007; 12: 2163-2173.
16. Hembrough TA, Ruiz JF, Swerdlow BM, et al. Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity. Blood 2004; 103: 3374-3380.
17. Mousa SA, Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost 2004; 92: 627-633.
18. Amirkhosravi A, Meyer T, Chang JY, et al. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost 2002; 87: 930-936.
19. Amirkhosravi A, Meyer T, Amaya M, et al. The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost 2007; 33: 643-652.
20. Zhang J, Piro O, Lu L, Broze GJ. Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation 2003; 108: 623-627.
21. Piro O, Broze GJ. Comparison of cell-surface TFPI alpha and beta. J Thromb Haemost 2005; 3: 2677-2683.
22. Hembrough TA, Swartz GM, Papathanassiu A, et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003; 63: 2997-3000.
23. Kamikubo YI, Nakahara Y, Takemoto S, Hamuro T, Miyamoto S, Funatsu A. Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. FEBS Lett 1997; 407: 116-120.
24. Hembrough TA, Ruiz JF, Papathanassiu AE, Green SJ, Strickland DK. Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor. J Biol Chem 2001; 276: 12241-12248.
25. Shirotani-Ikejima H, Kokame K, Hamuro T, Bu G, Kato H, Miyata T. Tissue factor pathway inhibitor induces expression of JUNB and GADD45B mRNAs. Biochem Biophys Res Commun 2002; 299: 847-852.
26. Storvold GL, Gjernes E, Askautrud HA, Borresen-Dale AL, Perou CM, Frengen E. A retroviral vector for siRNA expression in mammalian cells. Mol Biotechnol 2007; 35: 275-282.
27. Bendz BR, Andersen TO, Sandset PM. A new sensitive chromogenic substrate assay of tissue factor pathway inhibitor type 1. Thromb Res 2000; 97: 463-472.
28. Perl M, Chung CS, Ayala A. Apoptosis. Crit Care Med 2005; 33: S526-S529.
29. Kaufmann SH, Hengartner MO. Programmed cell death: Alive and well in the new millennium. Trends Cell Biol 2001; 11: 526-534.
30. Liang W, Cheng J, Liu R, et al. Peptide corresponding to the C terminus of tissue factor pathway inhibitor inhibits mesangial cell proliferation and activation in vivo. Peptides 2009; 30: 2330-2336.